Table 1:
Clinical Immunology Lab Findings Prior to and Following HCT
| Reference Range | Pre-HCT | 3 months post HCT | 1 year post HCT | 2 years post HCT | |
|---|---|---|---|---|---|
| CD3 (cells/μL) | 700–2100 | 1802 | 311 | 1171 | 1153 |
| CD4 (cells/μL) | 300–1400 | 1208 | 112 | 551 | 673 |
| CD8 (cells/μL) | 200–900 | 504 | 167 | 557 | 384 |
| CD4/CD45RA (cells/μL) | 41–1121 | 712 | 14 | 282 | -- |
| CD4/CD45RO (cells/μL) | 153–582 | 453 | 90 | 247 | -- |
| CD19 (cells/μL) | 100–500 | 499 | 172 | 1740 | 1182 |
| CD19+/CD27+/IgD- (cells/μL) | 9–102 | 13 | 0 | 3 | -- |
| NK (cells/μL) | 90–600 | 279 | 406 | 254 | 179 |
| IgG (mg/dL) | 635–1775 | 1240 | 755 | 744 | 809 |
| IgA (mg/dL) | 70–486 | 152 | 102 | 80 | 104 |
| IgM (mg/dL) | 71–237 | 132 | 54 | 42 | 57 |
| TREC (cells/μL) | ≥3061 | -- | 638 | 8663 | 9135 |
| PHA (% of control) | n/a | -- | 28% of control | 46% of control | >50% of control |
| Isohemagluttini ns | n/a | -- | -- | 1:16 | -- |
| Tetanus Titer (IU/mL) | ≥ 1 | 2.8 | |||
| Chimerism:PB MC | n/a | -- | 99% | 97% | -- |
| Chimerism:T | n/a | -- | 88% | 86% | -- |
| Chimerism:B | n/a | -- | 100% | 99% | -- |
| Chimerism:M | n/a | -- | 100% | 99% | -- |
Table 1: Clinical immunologic parameters pre- and post-HCT. Age-specific reference ranges are provided where appropriate. Post-transplant, the patient demonstrated excellent immune reconstitution, with normal T cell counts by 1 year and normal T cell proliferation to phytohemaglutinin by 2 years, as well as excellent response to tetanus vaccine challenge with protective titers at 2 years post transplant.